Is cisplatin eligibility status a factor in the prevalence of patients with UTUC receiving adjuvant therapy?


“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.

In this video, Shawn Dason, MD, FRCSC, discusses the background and findings of the study, “How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?” This study was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.

Related Videos
Mara R. Holton, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Crystal light -
Illustration of kidney stones | Image Credit: © freshidea -
United States Capitol Building | Image Credit: © rrodrickbeiler -
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.